Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Continuation of CDK4/6 inhibitor Palbociclib|DRUG: Discontinuation of CDK4/6 inhibitor Palbociclib|DRUG: Continuation of CDK4/6 inhibitor -Palbociclib|DRUG: Discontinuation of CDK4/6 inhibitor -Palbociclib|DRUG: Continuation of CDK4/6 inhibitor Abemaciclib|DRUG: Discontinuation of CDK4/6 inhibitor Abemaciclib
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest